Intranasal Heparin Treatment to Reduce Transmission Among Household Contacts of COVID 19 Positive Adults and Children

PHASE2/PHASE3Active, not recruitingINTERVENTIONAL
Enrollment

506

Participants

Timeline

Start Date

January 30, 2023

Primary Completion Date

December 9, 2024

Study Completion Date

June 30, 2026

Conditions
COVID-19
Interventions
DRUG

unfractionated heparin

intranasal

DRUG

0.9%sodium chloride

intranasal

Trial Locations (1)

3076

The Northern Hospital, Epping

All Listed Sponsors
collaborator

University of Melbourne

OTHER

collaborator

Northern Hospital, Australia

OTHER

collaborator

Monash University

OTHER

collaborator

The Peter Doherty Institute for Infection and Immunity

OTHER

collaborator

St Vincent's Hospital Melbourne

OTHER

lead

Murdoch Childrens Research Institute

OTHER